PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE Investigational New Drug Application
SALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that…
